Allakos Inc. – NASDAQ:ALLK

Allakos stock price today

$0.329
-0.97
-74.68%
Financial Health
0
1
2
3
4
5
6
7
8
9

Allakos stock price monthly change

+51.11%
month

Allakos stock price quarterly change

+51.11%
quarter

Allakos stock price yearly change

-52.55%
year

Allakos key metrics

Market Cap
113.46M
Enterprise value
235.27M
P/E
-0.84
EV/Sales
N/A
EV/EBITDA
-0.76
Price/Sales
N/A
Price/Book
0.88
PEG ratio
0.84
EPS
-2.45
Revenue
N/A
EBITDA
-192.56M
Income
-214.44M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Allakos stock price history

Allakos stock forecast

Allakos financial statements

Allakos Inc. (NASDAQ:ALLK): Profit margin
Jun 2023 0 -35.12M
Sep 2023 0 -45.62M
Dec 2023 10.75M -62.55M -581.55%
Mar 2024 0 -71.14M
Allakos Inc. (NASDAQ:ALLK): Analyst Estimates
Mar 2024 0 -71.14M
Sep 2025 0 -20.35M
Oct 2025 0 -20.54M
Dec 2025 0 -22.30M
  • Analysts Price target

  • Financials & Ratios estimates

Allakos Inc. (NASDAQ:ALLK): Debt to assets
Jun 2023 319196000 64.21M 20.12%
Sep 2023 283495000 62.45M 22.03%
Dec 2023 243610000 74.79M 30.7%
Mar 2024 177312000 73.32M 41.36%
Allakos Inc. (NASDAQ:ALLK): Cash Flow
Jun 2023 -32.59M 6.12M 0
Sep 2023 -29.47M 31.54M 1.07M
Dec 2023 -24.26M 20.18M 696K
Mar 2024 -32.54M 9.02M 132K

Allakos alternative data

Allakos Inc. (NASDAQ:ALLK): Employee count
Aug 2023 123
Sep 2023 123
Oct 2023 123
Nov 2023 123
Dec 2023 123
Jan 2024 123
Feb 2024 123
Mar 2024 131
Apr 2024 131
May 2024 131
Jun 2024 131
Jul 2024 131

Allakos other data

69.05% +7.17%
of ALLK is owned by hedge funds
37.16M +3.71M
shares is hold by hedge funds

Allakos Inc. (NASDAQ:ALLK): Insider trades (number of shares)
Period Buy Sel
Jun 2024 0 87064
Transaction Date Insider Security Shares Price per share Total value Source
Sale
RADFORD HARLAN BAIRD officer: Chief Financial Officer
Common Stock 87,064 $1.01 $87,935
Purchase
WALKER PAUL EDWARD director Common Stock 3,386,400 $5.02 $16,999,728
Purchase
WALKER PAUL EDWARD director Common Stock 597,600 $5.02 $2,999,952
Purchase
JANNEY DANIEL director, 10 percent owner
Common Stock 475,000 $5.02 $2,384,500
Option
JAMES STEVEN P director
Stock Option (Right to buy) 4,000 $0.53 $2,100
Sale
JAMES STEVEN P director
Common Stock 4,000 $108.12 $432,480
Option
JAMES STEVEN P director
Common Stock 4,000 $0.53 $2,100
Option
TOMASI ADAM officer: Presiden.. Common Stock 64,148 $4.31 $276,670
Option
TOMASI ADAM officer: Presiden.. Stock Option (Right to buy) 64,148 $4.31 $276,670
Sale
TOMASI ADAM officer: Presiden.. Common Stock 20,000 $0.69 $13,760
Patent
Application
Filling date: 31 Jul 2020 Issue date: 18 Aug 2022
Application
Filling date: 5 Nov 2021 Issue date: 26 May 2022
Application
Filling date: 14 Feb 2020 Issue date: 5 May 2022
Application
Filling date: 3 May 2019 Issue date: 12 Aug 2021
Application
Filling date: 31 Jul 2020 Issue date: 15 Apr 2021
Application
Filling date: 11 Jan 2019 Issue date: 25 Feb 2021
Grant
Filling date: 16 Jun 2016 Issue date: 15 Sep 2020
Application
Filling date: 4 May 2018 Issue date: 27 Aug 2020
Application
Filling date: 20 Feb 2020 Issue date: 11 Jun 2020
Application
Filling date: 4 May 2018 Issue date: 14 May 2020
Thursday, 19 December 2024
prnewswire.com
Monday, 11 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
Wednesday, 6 November 2024
globenewswire.com
Thursday, 10 October 2024
globenewswire.com
Wednesday, 7 August 2024
globenewswire.com
Wednesday, 26 June 2024
accesswire.com
Tuesday, 25 June 2024
globenewswire.com
accesswire.com
Monday, 24 June 2024
accesswire.com
Sunday, 23 June 2024
accesswire.com
Saturday, 22 June 2024
accesswire.com
Friday, 21 June 2024
accesswire.com
Thursday, 20 June 2024
accesswire.com
Wednesday, 19 June 2024
accesswire.com
Tuesday, 18 June 2024
accesswire.com
Monday, 17 June 2024
accesswire.com
Tuesday, 11 June 2024
accesswire.com
Sunday, 9 June 2024
accesswire.com
Saturday, 8 June 2024
accesswire.com
Friday, 7 June 2024
accesswire.com
Thursday, 6 June 2024
accesswire.com
Wednesday, 5 June 2024
accesswire.com
Tuesday, 4 June 2024
accesswire.com
Monday, 3 June 2024
accesswire.com
Sunday, 2 June 2024
accesswire.com
Saturday, 1 June 2024
accesswire.com
Friday, 31 May 2024
accesswire.com
Thursday, 30 May 2024
accesswire.com
Tuesday, 28 May 2024
globenewswire.com
  • What's the price of Allakos stock today?

    One share of Allakos stock can currently be purchased for approximately $0.33.

  • When is Allakos's next earnings date?

    Unfortunately, Allakos's (ALLK) next earnings date is currently unknown.

  • Does Allakos pay dividends?

    No, Allakos does not pay dividends.

  • How much money does Allakos make?

    Allakos has a market capitalization of 113.46M.

  • What is Allakos's stock symbol?

    Allakos Inc. is traded on the NASDAQ under the ticker symbol "ALLK".

  • What is Allakos's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Allakos?

    Shares of Allakos can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Allakos's key executives?

    Allakos's management team includes the following people:

    • Dr. Robert Alexander Ph.D. Chief Executive Officer & Director(age: 55, pay: $1,450,000)
    • Dr. Adam L. Tomasi Ph.D. Pres & Chief Operating Officer(age: 55, pay: $1,090,000)
    • Dr. Henrik Sandvad Rasmussen Strategic Advisor(age: 66, pay: $880,070)
    • Mr. Mark Asbury Chief Legal Officer & Gen. Counsel(age: 62, pay: $719,870)
  • How many employees does Allakos have?

    As Jul 2024, Allakos employs 131 workers.

  • When Allakos went public?

    Allakos Inc. is publicly traded company for more then 7 years since IPO on 19 Jul 2018.

  • What is Allakos's official website?

    The official website for Allakos is allakos.com.

  • Where are Allakos's headquarters?

    Allakos is headquartered at 975 Island Drive, Redwood City, CA.

  • How can i contact Allakos?

    Allakos's mailing address is 975 Island Drive, Redwood City, CA and company can be reached via phone at +65 05975002.

Allakos company profile:

Allakos Inc.

allakos.com
Exchange:

NASDAQ

Full time employees:

131

Industry:

Biotechnology

Sector:

Healthcare

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

975 Island Drive
Redwood City, CA 94065

CIK: 0001564824
ISIN: US01671P1003
CUSIP: 01671P100